

NCI Legislative Update

Clinical Trials Advisory Committee

Susan Erickson

Director, Office of Government and Congressional
Relations

November 4, 2009

Legislative Activities

Appropriations Information

Congressional Briefing

Legislation of Interest

FY 2010 Appropriations Activities

House

- NIH - \$31.3 Billion; NCI - \$ 5.15 Billion
- Passed by **House** July 24 (264-153)

Senate

- NIH - \$30.8 Billion; NCI - \$5.05 Billion
- Passed by **Appropriations** July 30 (29-1)

Next Steps

- Conference Comm. to reconcile differences

Appropriations – How Will it End?

Short term - New CR

Slightly longer term – New Strategy

Legislative Activities

Appropriations Information

Congressional Briefing

Legislation of Interest

Congressional Briefing

- Briefing on Prostate Cancer
 - Requested by Congressional Black Caucus
 - NCI presentation – Dr. Christine Berg
 - Discussed PLCO findings as they related to prostate cancer in African American men

Legislative Activities

Appropriations Information

Congressional Briefing

Legislation of Interest

Health Care Reform Bills

Provisions relevant to NCI - CER

- 2 Terms being used interchangeably
 - Comparative Effectiveness Research
 - Patient-Centered Outcomes Research
- 2 Strategies
 - Center for CER within AHRQ
 - HR 3200 (Dingell)
 - S 1679 (Harkin)
 - Non-Profit, Non-Government Corporation
 - S 1796 (Baucus)

SBIR Legislation

Extension/Reauthorization of Program

- HR 3614 (PL 111-66) provided temporary extension of program
- HR 2965 would extend program through 2011 and increase set-aside

Include SBIR set aside in ARRA

- S 1832 introduced by Sen. Mary Landrieu on Oct. 21.
 - Removes a provision from ARRA that exempts NIH from set aside for ARRA
 - Requires NIH to obligate \$150 M of ARRA to SBIR

National Cancer Institute

NCI Legislative Update

visit our website: <http://legislative.cancer.gov/>

U.S. DEPARTMENT
OF HEALTH AND
HUMAN SERVICES

National Institutes
of Health